AB-680
Based on 23 publication(s) in Google Scholar
AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.71%
- CAS No.: 2105904-82-1
- 화학식: C20H24ClFN4O9P2
- 분자량:580.82
-
보관:
-20°C, stored under nitrogen
* In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) AB-680
More- Cancer Res. 2025 Apr 15.
- Cancer Res. 2025 Feb 17;85(4):692-703. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Nat Commun. 2023 Jun 8;14(1):3364. [Abstract]
- Adv Sci (Weinh). 2023 Nov;10(33):e2302498. [Abstract]
- J Immunother Cancer. 2021 Jul;9(7):e002503. [Abstract]
- Cell Death Dis. 2025 Aug 4;16(1):587. [Abstract]
- Acta Pharmacol Sin. 2025 Jun 11. [Abstract]
- Cancer Immunol Res. 2023 Jan 3;11(1):56-71. [Abstract]
- NPJ Precis Oncol. 2025 Nov 18;9(1):358. [Abstract]
- Biomed Pharmacother. 2025 May 26:188:118188. [Abstract]
- Cell Rep. 2025 Nov 25;44(12):116623. [Abstract]
- Sci Signal. 2026 Mar 3;19(927):eadz6443. [Abstract]
- Front Immunol. 2022 Nov 21:13:1026994. [Abstract]
- Front Immunol. 2022 Oct 4:13:946871. [Abstract]
- Cells. 2024 Jun 29;13(13):1128. [Abstract]
- Front Pharmacol. 2026 Feb 12:17:1745656. [Abstract]
- J Cancer Res Clin Oncol. 2024 Jul 13;150(7):348. [Abstract]
- bioRxiv. 2026 Apr 8:2026.04.05.713683. [Abstract]
- Res Sq. 2026 Mar 5.
- bioRxiv. 2025 Jul 26:2025.07.22.666143. [Abstract]
- bioRxiv. 2023 Nov 1.
- Research Square Preprint. 2021 Mar.
Customer Validation & Images
-
ELISA
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
IHC
Biological Activity
AB-680 (AB680) inhibits soluble hCD73 with an IC50 of 0.043 nM, also inhibits hCD73 in CHO cells, suppresses CD73 in human, mouse CD8+ T Cells and hPBMC, with IC50s of 0.070, 0.008, 0.66 and 0.011 nM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2105904-82-1
-
Appearance Solid
-
분자량 580.82
-
화학식 C20H24ClFN4O9P2
-
Color White to off-white
-
SMILES
O=P(CP(O)(O)=O)(O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(Cl)C=C3N[C@H](C4=CC=CC=C4F)C)=C3C=N2)O1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, stored under nitrogen
* In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen)
Publications (23)
-
Journal Impact Factor
-
Most Recent
-
-
Cancer Res
Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis. [Abstract]2025 Feb 17;85(4):692-703. PMID: 39652568
AB-680 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Feb 17;85(4):692-703. [Abstract]
IFNγ levels measured by ELISA in supernatant of NY-ESO/624mel cultures exposed to AMP (300 μmol/L) with or without AB-680 (0.5 μmol/L) for 24 hous.
AB-680 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Feb 17;85(4):692-703. [Abstract]
Percentage of labeled (M + 5) ADO and AMP out of total intracellular adenosine (ADO) in activated (1 ng/mL αCD3) NY-ESO-1–specific T cells exposed to isotopically labeled 15N5-AMP for 3 hours in presence or not of either AB-680 (0.5 μmol/L).
-
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Nat Commun
Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner. [Abstract]2023 Jun 8;14(1):3364. PMID: 37291128 -
Adv Sci (Weinh)
Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Cancer. [Abstract]2023 Nov;10(33):e2302498. PMID: 37867243
AB-680 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Nov;10(33):e2302498. [Abstract]
Image, volumes, and weights of the AB-680 (20 mg/kg; i.p.; once weekly for 3 weeks)‐treated versus Control KPC subcutaneous allografts (n = 6 samples per group).
AB-680 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Nov;10(33):e2302498. [Abstract]
Representative images of H&E staining, Masson's trichrome staining (MTS), and immunohistochemistry staining of CD8, Granzyme B, α‐SMA. Scale bar: 200 µm. The results showed that AB-680 (20 mg/kg; i.p.; once weekly for 3 weeks) significantly increased the numbers of CD8+ and Granzyme B+ cells.
AB-680 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Nov;10(33):e2302498. [Abstract]
Representative images of immunohistochemistry staining of CXCL5 and CXCR2 in the KPC tumors from the indicated treatment groups. The results showed that AB-680 (20 mg/kg, i.p.; once weekly) also increased the percentage of the corresponding receptor CXCR2+ area in treated tumors.
-
J Immunother Cancer
Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer. [Abstract]2021 Jul;9(7):e002503. PMID: 34253638 -
Cell Death Dis
P2X7 a new therapeutic target to block vesicle-dependent metastasis in colon carcinoma: Role of the A2A/CD39/CD73 axis. [Abstract]2025 Aug 4;16(1):587. PMID: 40759630 -
Acta Pharmacol Sin
CD73 inhibitor AB680 suppresses glioblastoma in mice by inhibiting purine metabolism and promoting P2RY12+ microglia transformation. [Abstract]2025 Jun 11. PMID: 40500344 -
Cancer Immunol Res
2023 Jan 3;11(1):56-71. PMID: 36409930 -
NPJ Precis Oncol
Metabolomic and transcriptomic profiling of HNSCC identifies AMIGO2 as a therapeutic target modulating tumor microenvironment. [Abstract]2025 Nov 18;9(1):358. PMID: 41254143 -
Biomed Pharmacother
Co-targeting the CD73-adenosinergic axis enhances the anti-tumor efficacy of anti-PD-L1 immunotherapy in bladder cancer. [Abstract]2025 May 26:188:118188. PMID: 40424822 -
Cell Rep
Fatty acids modulate the colorectal cancer immune microenvironment via regulating the interaction and transactivation of PPARα/δ and P53. [Abstract]2025 Nov 25;44(12):116623. PMID: 41296567 -
Sci Signal
Glucose metabolism sustains aberrant STAT3 signaling in colorectal cancer through glycosylated local signaling factors. [Abstract]2026 Mar 3;19(927):eadz6443. PMID: 41774818 -
Front Immunol
Human gut microbiota-reactive DP8α regulatory T cells, signature and related emerging functions. [Abstract]2022 Nov 21:13:1026994. PMID: 36479125 -
Front Immunol
CD38+CD39+ NK cells associate with HIV disease progression and negatively regulate T cell proliferation. [Abstract]2022 Oct 4:13:946871. PMID: 36268017 -
Cells
Inhibition of Vascular Smooth Muscle Cell Proliferation by ENPP1: The Role of CD73 and the Adenosine Signaling Axis. [Abstract]2024 Jun 29;13(13):1128. PMID: 38994980 -
Front Pharmacol
ACT001 synergizes with temozolomide-based chemoradiotherapy to cure refractory glioblastoma by targeting TNF-CXCL10-CD8+ T-cell immunity. [Abstract]2026 Feb 12:17:1745656. PMID: 41769685 -
J Cancer Res Clin Oncol
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma. [Abstract]2024 Jul 13;150(7):348. PMID: 39002018 -
bioRxiv
Serial Thermal Ablation Induces Abscopal Antitumor Immunity and Reveals Targetable CSF1R-Dependent Resistance in Pancreatic Cancer. [Abstract]2026 Apr 8:2026.04.05.713683. PMID: 41993287 -
-
bioRxiv
Glucose Metabolism Sustains Aberrant STAT3 Signaling in Colorectal Cancer via Glycosylated Paracrine Factors. [Abstract]2025 Jul 26:2025.07.22.666143. PMID: 40777356 -
-
용액&용해도
DMSO : 100 mg/mL (172.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 5 mg/mL (8.61 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.30 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.30 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 1% DMSO 99% Saline
Solubility: ≥ 0.5 mg/mL (0.86 mM); Clear solution
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.7217 mL | 8.6085 mL | 17.2170 mL | 43.0426 mL |
| 5 mM | 0.3443 mL | 1.7217 mL | 3.4434 mL | 8.6085 mL | |
| DMSO | 10 mM | 0.1722 mL | 0.8609 mL | 1.7217 mL | 4.3043 mL |
| 15 mM | 0.1148 mL | 0.5739 mL | 1.1478 mL | 2.8695 mL | |
| 20 mM | 0.0861 mL | 0.4304 mL | 0.8609 mL | 2.1521 mL | |
| 25 mM | 0.0689 mL | 0.3443 mL | 0.6887 mL | 1.7217 mL | |
| 30 mM | 0.0574 mL | 0.2870 mL | 0.5739 mL | 1.4348 mL | |
| 40 mM | 0.0430 mL | 0.2152 mL | 0.4304 mL | 1.0761 mL | |
| 50 mM | 0.0344 mL | 0.1722 mL | 0.3443 mL | 0.8609 mL | |
| 60 mM | 0.0287 mL | 0.1435 mL | 0.2870 mL | 0.7174 mL | |
| 80 mM | 0.0215 mL | 0.1076 mL | 0.2152 mL | 0.5380 mL | |
| 100 mM | 0.0172 mL | 0.0861 mL | 0.1722 mL | 0.4304 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
AB-680 Related Classifications
HY-125286 Related Classifications
Powered by Bioz